Goldman Sachs price target reduction

What happened: On May 27, 2026, Goldman Sachs reduced its price target for Intuitive Surgical (ISRG) to $558 from $621, maintaining a 'Buy' rating. Earlier, on May 7, the firm trimmed its price target for Insulet Corporation (PODD) to $237 from $277, despite strong Q1 results, keeping the rating unchanged.

Market impact: The price target reductions suggest a reassessment of valuations in the MedTech sector, affecting ISRG and PODD. Despite maintaining 'Buy' ratings, the lower targets indicate potential short-term headwinds for these stocks.

What to watch next: ISRG's Q2 earnings, scheduled for July 21, 2026, will provide insights into its growth trajectory. For PODD, the upcoming Q2 results on August 3, 2026, will be crucial to assess the impact of the valuation revision.